Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit

Corporate presentation and live webcast scheduled for June 10, 2020 at 2:10 pm ET

Oragenics, Inc. (NYSE American: OGEN), announced today that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc., will give a virtual corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9th to 12th, 2020.

The presentation will be held on Wednesday, June 10, 2020 at 2:10 pm ET, followed by a live Q&A session with registered investors and other conference attendees. A live webcast of the presentation will be available here https://www.webcaster4.com/Webcast/Page/2038/35043. Dr.. Joslyn will be available for one-on-one meetings online as well. Interested investors may request a meeting time by emailing: laura@investorsummitgroup.com.

About Oragenics, Inc.

Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease and oral mucositis. Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from the novel coronavirus, SARS-CoV-2, which causes COVID-19. The TerraCoV2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health, which issued a worldwide, nonexclusive intellectual property license to Noachis Terra. In addition, Oragenics also has two exclusive worldwide channel collaborations, one with Precigen, Inc.’s subsidiaries relating to the treatment of oral mucositis and the other with ILH Holdings, Inc., relating to the development of novel antibiotics.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement

Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005242/en/

Contacts

Corporate:
Michael Sullivan, 813-286-7900
Chief Financial Officer
msullivan@oragenics.com

or

Investors:
John Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com

Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com